Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MMA Embolization for Refractory Chronic Migraine

NCT: NCT06735833 · RECRUITING

NCT IDNCT06735833
StatusRECRUITING
Start Date2025-04-23
Completion2029-07-31
SponsorCerenovus, Part of DePuy Synthes Products, Inc. (INDUSTRY)
First posted
Last updated

Brief Summary

This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑